ASH 2023 | Management of RT patients previously exposed to multiple lines of therapy
Adam Kittai, MD, Ohio State University, Columbus, OH, discusses the management of Richter’s transformation (RT) and highlights the need to enroll patients who have received previous small molecule inhibitors into clinical trials, as these individuals tend to have worse outcomes compared to untreated patients. Dr Kittai outlines some of the clinical trials that are ongoing in patients with RT, and he looks forward to the presentation of the findings in years to come. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Eli Lilly, BeiGene, AstraZeneca, AbbVie, Janssen, KITE, BMS
Research Funding,: BeiGene, AstraZeneca
Speakers Bureau: BeiGene
